ID   LaNCE hiPSC-39
AC   CVCL_WR89
SY   hiPSC-39; iPS-39-PLS; iPS-39; iPS-PD2; LANCEi015-A
DR   hPSCreg; LANCEi015-A
DR   Wikidata; Q95981250
RX   PubMed=29433076;
RX   PubMed=31710912;
CC   From: National Laboratory of Embryonic Stem Cell (LaNCE), University of Sao Paulo; Sao Paulo; Brazil.
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
ST   Source(s): PubMed=29433076
ST   Amelogenin: X,Y
ST   CSF1PO: 11,12
ST   D13S317: 12
ST   D16S539: 11
ST   D18S51: 14,17
ST   D19S433: 13,14
ST   D21S11: 29,31.2
ST   D2S1338: 24,25
ST   D3S1358: 15,16
ST   D5S818: 11,13
ST   D7S820: 8,10
ST   D8S1179: 13
ST   FGA: 19,28
ST   TH01: 8,9
ST   TPOX: 9
ST   vWA: 15,18
DI   NCIt; C26845; Parkinson's disease
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   70Y
CA   Induced pluripotent stem cell
DT   Created: 05-07-19; Last updated: 29-06-23; Version: 5
//
RX   PubMed=29433076; DOI=10.1016/j.scr.2018.01.030;
RA   Sarafian R.D., Morato-Marques M., Borsoi J., Pereira L.V.;
RT   "Monitoring cell line identity in collections of human induced
RT   pluripotent stem cells.";
RL   Stem Cell Res. 28:66-70(2018).
//
RX   PubMed=31710912; DOI=10.1016/j.scr.2019.101640;
RA   Tofoli de Araujo F., Chien H.-F., Barbosa E.R., Pereira L.V.;
RT   "Generation of 5 hiPSC lines derived from three unrelated idiopathic
RT   Parkinson disease patients and two unrelated healthy control
RT   individuals.";
RL   Stem Cell Res. 41:101640-101640(2019).
//